Evidence map›Paper›PMID 40175909›Full record

Trial reportBMC anesthesiology2025

Comparison between single bolus dose administration and continuous infusion of remimazolam for general anesthesia induction in non-cardiac surgery: a single-center prospective randomized controlled trial.

Tsuyoshi Ikeda, Hirotsugu Miyoshi, Kenshiro Kido, Ayako Sumii, Sachiko Otsuki, Takahiro Kato, Ryuji Nakamura, Soshi Narasaki, Yasuo M Tsutsumi

Abstract readRandomized Controlled TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tsuyoshi IkedaDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.
Hirotsugu MiyoshiDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan. h-miyoshi@hiroshima-u.ac.jp.
Kenshiro KidoDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.
Ayako SumiiDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.
Sachiko OtsukiDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.
Takahiro KatoDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.
Ryuji NakamuraDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.
Soshi NarasakiDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.
Yasuo M TsutsumiDepartment of Anesthesiology and Critical Care, Hiroshima University, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRemimazolam is a short-acting benzodiazepine anesthetic recommended for continuous infusion during anesthesia induction. However, the safety and efficacy of single bolus dose administration remain under investigation. This study compared continuous infusion with single bolus dose administration and assessed the safety of a single bolus dose administration.

methodsThe participants were randomly assigned into three groups based on the method of remimazolam administration the day before surgery: (1) continuous infusion group (continuous infusion at 12 mg/kg/h), (2) single bolus dose administration of 0.1 group (single administration of 0.1 mg/kg), or (3) single bolus dose administration of 0.2 group (single administration of 0.2 mg/kg). The time between drug administration and loss of consciousness was determined, and hemodynamic monitoring was performed.

results67 patients (continuous infusion group (n = 22), single bolus dose administration of 0.1 group (n = 22), and single bolus dose administration of 0.2 group (n = 23)) were included in the study. The different times to loss of consciousness were 88.2 ± 16.2 s, 59.5 ± 31.5 s, and 42.6 ± 11.4 s in the continuous infusion group, single bolus dose administration of 0.1 group, and single bolus dose administration of 0.2 group, respectively. No significant differences were observed in the incidence of adverse events between the groups. The results are presented as mean ± standard deviation (SD).

conclusionsSingle-dose remimazolam is a safe method for anesthesia induction, resulting in shorter time to loss of consciousness compared with continuous infusion, while maintaining a similar incidence of adverse events.

trial registrationjRCTs061230049, registered on 17/08/2023.

Indexed as

Anesthesia, GeneralBenzodiazepinesAdultAgedFemaleHumansInfusions, IntravenousMaleMiddle AgedProspective StudiesBenzodiazepinesremimazolamIntravenous anesthesiaRapid inductionRapid sequence inductionRemimazolam

Identifiers

PMID40175909
PMCPMC11963264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.